Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Inicio Explorar nav.journalClub Tendencias

⌘+K

Clinical features, treatment, and outcome of nivolumab induced cholangitis | Synapse

September 9, 2024Immunopharmacology and Immunotoxicology26 citations

Clinical features, treatment, and outcome of nivolumab induced cholangitis

Ver artículo completo

YHYang HeSoochow University ZFZhiqiang FanFirst Affiliated Hospital of Hunan University of Traditional Chinese Medicine WSWei SunCentral South University

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Cholangitis is an uncommon and severe adverse reaction of nivolumab with unclear clinical features. The purpose of this study was to investigate the clinicopathological features, imaging, and treatment of nivolumab-induced cholangitis.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

He et al. (2024) studied this question.

synapsesocial.com/papers/68e58ff8b6db64358752bb36 https://doi.org/https://doi.org/10.1080/08923973.2024.2402338

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case2022 · 13 citations
2Nivolumab‐related pancreatitis with autoimmune pancreatitis‐like imaging features2019 · 20 citations
3Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology2022 · 427 citations
4EASL Clinical Practice Guidelines: Autoimmune hepatitis2015 · 1,268 citations
5Hepatology Clinical2022 · 4 citations